The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy
Open accessAbstract
For 50 years the dosing of anticancer drugs has been empirical— small phase I trials predict a tolerable dose, and subsequent studies refine the accuracy of that prediction. Because of population variability, however, a proportion of patients will inevitably experience more severe toxicity at doses selected for general use. Phase III trials routinely report grade 4 myelosuppression rates of up to 80% in certain solid tumors, without a recommendation for a dose adjustment. Historically, this risk has been regarded as acceptable, compared with the greater risk of treating the greater part of the population with ineffective doses. Approaches to individualizing therapy have been sought through pharmacokinetic analyses, but recommendations to the community have never been practical. In recent years, the potential of pharmacogenetic analyses to improve the therapeutic index of cancer therapy in pediatric malignancies has been described. For example, thiopurines are subject to variable metabolic disposition through single nucleotide polymorphisms (mutations in a gene sequence that have a prevalence of at least 1%). Clinical studies have shown that identification of the variant population has the potential to ameliorate toxicity while enhancing therapeutic outcome. Similar genetic signatures have long been sought in adult solid tumors. In colorectal cancer, several candidate genes have been identified that have the potential to determine risk of toxicity and possibly efficacy of fluoropyrimidines and oxaliplatin. Such approaches have two distinct goals: to minimize toxicity and to maximize the effectiveness of therapy. In 2005, the US Food and Drug Administration (FDA) took two actions that may be perceived as an advance regarding how pharmacogenetic approaches might permit us to reduce the risk of chemotherapy. First, it was determined that a fraction of the population at higher risk for adverse effects associated with the use of standard doses of irinotecan can be identified prospectively. These are patients who, by virtue of a genetic polymorphism, have a lower than normal capacity to metabolize SN-38, the active metabolite of irinotecan. The polymorphism is found in the gene encoding uridine diphosphate glucuronosyltransferase (UGT) 1A1, which facilitates the excretion of SN-38. This risk was emphasized by a warning added to the package insert of irinotecan. The text added to the label states that “individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. A reduced initial dose should be considered for patients known to be homozygous for the UGT1A1*28 allele.” Second, the FDA approved a test to identify these individuals. The genetic test (Invader UGT1A1 Molecular Assay; Third Wave Technologies Inc, Madison, WI), conducted on genomic DNA isolated from peripheral blood, identifies patients homozygous for the UGT1A1*28 allele. Such patients clear irinotecan and its metabolites more slowly than the rest of the population, and so have greater exposure to active drug after a standard dose. The FDAapproved label for the test states that “a reduced initial dose [of irinotecan] should be considered for patients known to be homozygous for the UGT1A1*28 allele.” What are practicing oncologists to do with this information?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Metadata
- Authors
- O'Dwyer, P. J., & Catalano, R. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-10-01
- Volume
- 24
- Issue
- 28
- Pages
- 4534-4538
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121917437
- Cited by
- 166
- References
- 2
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy. https://app.cochat.ai/papers/10.1200/jco.2006.07.3031
- The paper
- O'Dwyer, P. J., & Catalano, R. B. (2006). Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.07.3031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.